

AMENDMENTS TO CLAIMS

Claims 1 to 27. (Cancelled).

Claim 28. (Cancelled).

Claim 29. (Withdrawn) The method as defined in Claim 28 where in the pharmaceutical composition administered the statin and aspirin are formulated together in a single tablet.

Claim 30. (Withdrawn) The method as defined in Claim 29 wherein the tablet administered includes a core and a coating layer surrounding said core and wherein one of the statin and aspirin is present in the core and the other is present in the coating layer surrounding the core.

Claim 31. (Withdrawn) The method as defined in Claim 30 wherein the aspirin is present in the core and the statin is present in the coating layer.

Claim 32. (Withdrawn) The method as defined in Claim 31 wherein the coating layer also includes one or more buffering agents.

Claim 33. (Withdrawn) The method as defined in Claim 46 wherein the statin is pravastatin.

Claim 34. (Withdrawn) The method as defined in Claim 46 wherein the pharmaceutical composition administered further includes one or more buffering agents in combination with the statin.

Claim 35. (Withdrawn) The method as defined in Claim 29 wherein the tablet administered further includes an outer protective coating or finishing layer surrounding said tablet.

Claim 36. (Previously Amended) The method as defined in Claim 46 wherein the aspirin in the pharmaceutical composition administered is in the form of enteric ~~coating~~ coated granules.

Claim 37. (Cancelled).

Claim 38. (Previously Presented) The method as defined in Claim 36 wherein the enteric coated aspirin granules include a finishing overcoat, and the coated aspirin and the statin are in the form of a table or capsule.

Claim 39. (Previously Presented) The method as defined in Claim 38 wherein the coated aspirin granules and the statin in the form of granules are contained in the same capsule shells.

Claim 40. (Currently Amended) The method as defined in Claim 28 46 wherein in the pharmaceutical composition administered the aspirin is in the form of enteric coated granules of aspirin and the statin is in the form of enteric coated granules of statin, in the form of compressed tablets or capsules.

Claim 41. (Cancelled).

Claim 42. (Previously Presented) The method as defined in Claim 46 wherein the statin is in the form of enteric coated statin granules.

Claim 43. (Previously Presented) The method as defined in Claim 46 wherein the statin granules include an outer protective coating to protect against interaction with the aspirin.

Claim 44. (Previously Presented) The method as defined in Claim 46 wherein the pharmaceutical composition administered further includes an antioxidant.

Claim 45. (Previously Presented) The method as defined in Claim 44 wherein the antioxidant is vitamin C and/or vitamin E.

Claim 46. (Previously Presented) A method for lowering serum cholesterol or inhibiting or treating atherosclerosis or reducing risk of or treating a cardiovascular event or disease, coronary artery disease or cerebrovascular disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a pharmaceutical composition comprising a combination of a statin cholesterol lowering agent and aspirin in a single dosage form, which dosage form reduces interaction between the statin and the aspirin, wherein the pharmaceutical composition is in the form of a tablet or capsule containing both aspirin granules and statin granules.

Claim 47. (Previously Presented) The method as defined in Claim 46 wherein the statin employed is pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin.